Cortisol And Chronic Pain Research

Last updated: October 4, 2026 - Reviewed by Verdant Wellness Editorial Team

RD

By Gabriela Mitchell, Registered Dietitian (Linkedin)

Last Updated September 2026  ·  29 min read

10% off · weekly tips

Real science on cortisol, stress, and sleep.

Send it →

---

Table of Contents

• What Is the HPA Axis and Why Does It Matter for Pain?
• The Cortisol-Pain Relationship: Cause or Consequence?
• Diurnal Cortisol Rhythm and Chronic Pain Risk
• The 2025 Landmark Cohort Study Explained
• Cortisol and Central Sensitization
• Cortisol Fibromyalgia Research: What We Know
• Cortisol Pain Sensitivity: The Neuroscience
• HPA Pain Research in Specific Conditions
• Stress, Trauma, and the Cortisol-Pain Nexus
• Is Cortisol a Useful Biomarker for Chronic Pain?
• Confounders: Sleep, Depression, Anxiety, and Age
• What Treatments Can Normalize Cortisol in Chronic Pain?
• Clinical Takeaways for Practitioners and Patients
• Frequently Asked Questions

---

Introduction

If you have ever sat with a patient who has persistent pain and wondered what is happening beneath the surface at a neuroendocrine level, you are not alone. For decades, researchers have suspected that the body's primary stress hormone — cortisol — plays a meaningful role in the development, maintenance, and amplification of chronic pain. But the precise nature of that relationship has remained frustratingly elusive.

Is cortisol too high, or too low? Does chronic pain raise cortisol, or does abnormal cortisol predispose someone to chronic pain? Is the problem a single elevated reading, or something more subtle — a disrupted pattern of secretion across the day?

New cortisol and chronic pain research published between 2024 and 2025 is beginning to give us clearer answers, and those answers are reshaping how clinicians think about pain neuroscience. This post synthesizes the most rigorous evidence available, explains the underlying biology in accessible terms, and gives you actionable insights whether you are a physiotherapist, psychologist, pain physician, or a person living with persistent pain yourself.

Let's start with the foundation.

---

What Is the HPA Axis and Why Does It Matter for Pain?

The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress-response system. When the brain perceives a threat — whether physical injury, psychological stress, infection, or sleep deprivation — the hypothalamus releases corticotropin-releasing hormone (CRH). This signals the anterior pituitary to secrete adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal cortex to produce cortisol.

Under normal circumstances, this cascade is elegant. Cortisol mobilizes glucose for energy, modulates the immune response, sharpens attention, and — critically for our purposes — suppresses pain and inflammation in the short term. After the threat passes, cortisol feeds back to the hypothalamus and pituitary to shut the system down, a process called negative feedback inhibition.

The Normal Diurnal Cortisol Rhythm

Cortisol does not stay flat throughout the day. In healthy adults, it follows a pronounced diurnal pattern:

• Peak at waking: Cortisol surges sharply within 20–40 minutes of waking, a phenomenon called the cortisol awakening response (CAR)
• Steep morning decline: Levels fall steeply over the first 4–5 hours
• Gradual afternoon and evening decline: Cortisol continues dropping to its lowest point (nadir) around midnight

This rhythm is not decorative. It coordinates metabolic function, immune activity, inflammation suppression, and pain sensitivity across the 24-hour cycle. When this rhythm becomes flattened, blunted, or disrupted — as happens in prolonged stress, trauma, burnout, and many chronic disease states — the downstream consequences are wide-ranging.

HPA pain research has consistently identified that people with chronic pain conditions show measurable deviations from this normal diurnal pattern. The direction and magnitude of those deviations vary by condition, and that variability has been a major source of confusion in the literature, a point we will return to repeatedly.

---

The Cortisol-Pain Relationship: Cause or Consequence?

One of the most fundamental questions in cortisol chronic pain research is the direction of causality. Does chronic pain itself dysregulate the HPA axis as a downstream consequence of persistent nociception and suffering? Or does pre-existing HPA dysfunction lower the threshold for pain to become chronic in the first place?

The honest answer, based on current evidence, is: probably both, interacting in a bidirectional loop.

Evidence for Cortisol Dysregulation as a Consequence of Chronic Pain

Prolonged pain is an undeniable psychological and physiological stressor. People living with persistent pain frequently experience:

• Disrupted sleep
• Elevated depression and anxiety
• Reduced physical activity
• Social isolation and occupational impairment

Each of these independently dysregulates the HPA axis. It would be surprising if months or years of living with chronic pain did not alter cortisol patterns.

A 2020 systematic review examining cortisol findings across osteoarthritis and chronic pain literature found inconsistent results overall. Three low-quality studies did suggest increased cortisol levels in people with pain, but the review's authors noted a high risk of bias across these studies and warned against drawing firm conclusions (PubMed 32156623). This finding is an important reminder that not all cortisol-pain associations survive rigorous methodological scrutiny.

Evidence for HPA Dysfunction as a Precursor to Chronic Pain

More compelling for clinical practice is the emerging prospective evidence — that is, studies that measure cortisol before chronic pain develops and then follow people over time to see who develops it.

This is exactly what the landmark 2025 cohort study (discussed in detail below) did, and its findings strongly suggest that diurnal cortisol disruption can precede and predict the later onset of chronic multisite pain, not merely reflect it.

Additionally, a 2024 MIDUS (Midlife in the United States) study reported higher late-day cortisol levels in people with chronic pain, consistent with HPA-axis dysregulation that may perpetuate or amplify the pain experience (Stress 27:1, article 2402954). Elevated late-day cortisol is a sign that the normal suppression mechanism is impaired — the brake on the stress response is not working properly.

The chronic pain HPA relationship, in other words, is best understood as a reinforcing cycle rather than a simple linear cause-and-effect.

---

★★★★★ 4.8 · 1,247 reviews

Feel Calm By Bedtime. Focused By Morning.

Adaptogen-based formula. Third-party tested. Made in an FDA-registered facility. Backed by a 60-day money-back guarantee.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Diurnal Cortisol Rhythm and Chronic Pain Risk

If researchers were looking for a single cortisol number to use as a biomarker, the literature has largely disappointed them. A single morning cortisol reading, or even a 24-hour urinary cortisol level, does not reliably discriminate between people with and without chronic pain.

What does show a more consistent signal is the shape of the cortisol curve across the day — specifically, whether the post-waking decline is appropriately steep or pathologically blunted.

What Is a Blunted Diurnal Cortisol Rhythm?

A blunted or flattened diurnal rhythm means the usual steep morning drop does not occur, or occurs incompletely. Instead of cortisol rapidly declining from its morning peak down to low afternoon levels, levels remain relatively elevated and flat throughout the day.

This pattern has been documented in:

• Chronic fatigue syndrome
• Burnout
• Post-traumatic stress disorder (PTSD)
• Major depression
• Rheumatoid arthritis
• And increasingly, in people with or at risk for chronic pain

The significance of a blunted rhythm for pain may relate to several mechanisms. Cortisol's anti-inflammatory effects depend partly on the size of its diurnal swing — low-amplitude cortisol rhythms may impair the body's ability to suppress inflammatory mediators that sensitize nociceptors. Additionally, the rhythm synchronizes neuroimmune activity; when it becomes disorganized, pain-modulating circuits may lose their normal temporal regulation.

The MIDUS Study: Late-Day Cortisol Elevation

The 2024 MIDUS study, drawing from a large community-based cohort of midlife Americans, found a consistent pattern of higher late-day cortisol levels among participants with chronic pain compared to pain-free individuals. This finding is consistent with a flattened or shifted diurnal profile — the cortisol curve has not declined appropriately by late afternoon and evening.

This matters because late-day cortisol elevation may:

• Impair sleep architecture and slow-wave sleep
• Amplify central sensitization processes overnight
• Interact with inflammatory cytokine release cycles
• Perpetuate the stress-pain reinforcing loop

The MIDUS findings align with broader HPA pain research suggesting that it is the temporal pattern of cortisol secretion, not merely its average level, that matters most for pain biology.

The 2025 Landmark Cohort Study Explained

The most significant recent contribution to cortisol and chronic pain research was published in 2025 (PubMed 40484158): "Association of Diurnal Cortisol Rhythm with Chronic Pain: Evidence from a Prospective Cohort Study in Community-Dwelling Adults."

This study is worth examining in detail because its prospective design allows stronger causal inference than most previous work.

Study Design

• Design: Prospective cohort study
• Population: Community-dwelling adults (not recruited from pain clinics)
• Follow-up: Median 7.6 years
• Cortisol assessment: Salivary samples collected across the waking day to characterize the diurnal rhythm
• Outcome: Development of chronic multisite pain and chronic non-multisite pain

The key exposure variables were measures of cortisol decline after waking — specifically the rate of decline during the early post-wake period (0–1.5 hours) and the mid post-wake period (0.5–4.5 hours).

Key Findings

The results were striking and internally consistent:

Finding 1 — Blunted early post-wake cortisol decline: A blunter cortisol decline in the 0.5–4.5 hour window after waking was associated with nearly twice the odds of developing chronic multisite pain over the follow-up period:

OR 2.16 (95% CI 1.41–3.32)

Finding 2 — Blunted mid post-wake cortisol decline: The mid post-wake blunting was also independently associated with chronic multisite pain:

OR 1.93 (95% CI 1.28–2.90)

Finding 3 — Subgroup specificity: When the analysis was stratified by pain type, blunted early post-wake cortisol decline was specifically and more strongly associated with chronic multisite pain rather than chronic non-multisite (localized) pain:

OR 2.73 (95% CI 1.49–4.99)

Why Multisite Pain Specifically?

The selectivity for multisite pain is biologically plausible and theoretically important. Chronic multisite pain is more closely associated with central sensitization — a state where the central nervous system becomes amplified in its pain processing — than localized chronic pain, which may be more peripherally driven.

This specificity suggests that the cortisol rhythm disruption may be acting through central mechanisms of pain amplification rather than through peripheral inflammatory pathways alone. This hypothesis aligns with cortisol's known roles in regulating neuroinflammation and central sensitization, discussed in the next section.

What This Study Means in Practice

Before these findings were available, the literature supported a cross-sectional association between cortisol and pain, but could not establish temporal sequence. This prospective study, with its 7.6-year follow-up, makes a compelling case that disrupted diurnal cortisol precedes the onset of widespread chronic pain.

This reframes cortisol rhythm disruption as a potential risk factor that could theoretically be identified and addressed before chronic pain becomes established.

Cortisol and Central Sensitization

Cortisol central sensitization research represents one of the most mechanistically interesting frontiers in pain neuroscience. To understand why, we need a brief primer on central sensitization.

What Is Central Sensitization?

Central sensitization (CS) is a state of amplified neural signaling within the central nervous system that results in pain hypersensitivity, allodynia (pain from normally non-painful stimuli), and widespread pain beyond the site of injury. It underpins conditions like fibromyalgia, complex regional pain syndrome, chronic widespread pain, and many cases of non-specific low back pain.

Key mechanisms include:

• Long-term potentiation at spinal cord synapses
• Reduced descending inhibitory control (e.g., from the periaqueductal gray)
• Microglial activation and neuroinflammation
• Altered thalamic gating of pain signals
• Changes in NMDA receptor sensitivity

Where Does Cortisol Fit?

Cortisol interacts with central sensitization through several pathways:

1. Glucocorticoid receptors in pain-modulating circuits Glucocorticoid receptors are densely expressed in the hippocampus, prefrontal cortex, amygdala, and spinal cord dorsal horn — all structures critically involved in pain modulation. Chronic exposure to dysregulated cortisol can alter receptor sensitivity (glucocorticoid receptor downregulation), impairing the anti-inflammatory and pain-suppressive actions of cortisol.

2. Neuroinflammation Chronically dysregulated cortisol impairs the body's ability to suppress pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). These cytokines directly sensitize peripheral nociceptors and activate spinal cord microglia, driving central sensitization.

3. HPA-sympathoadrenal interactions The HPA axis does not operate in isolation. Chronic pain activates both the HPA axis and the sympathetic nervous system (the "fight-or-flight" branch). Dysregulated cortisol disrupts the normal coordination between these systems, which may amplify pain signaling.

4. Descending pain modulation The prefrontal cortex exerts top-down inhibitory control over spinal cord pain processing. Chronic cortisol dysregulation impairs prefrontal function — reducing cognitive control over pain, weakening descending inhibition, and potentially facilitating central sensitization.

5. Sleep architecture disruption Blunted diurnal cortisol rhythms are closely associated with disrupted sleep, particularly reduced slow-wave sleep. Sleep disturbance is itself a potent driver of central sensitization. This creates another reinforcing loop: cortisol dysregulation → poor sleep → increased central sensitization → worsened pain.

The specificity of the 2025 cohort study's findings for multisite chronic pain — the phenotype most closely associated with central sensitization — supports these mechanistic hypotheses.

Cortisol Fibromyalgia Research: What We Know

Fibromyalgia is arguably the chronic pain condition most closely associated with central sensitization, and cortisol fibromyalgia research has been ongoing for over two decades. The findings have been enlightening, but also frustratingly heterogeneous.

What the Earlier Literature Found

Early studies in the 1990s and 2000s often reported hypocortisolism in fibromyalgia — lower-than-normal basal cortisol levels, attenuated cortisol responses to stress, and blunted CAR. This was frequently interpreted as HPA axis "exhaustion" following prolonged stress exposure.

However, not all studies replicated these findings. Some found elevated cortisol; others found no significant difference from controls. The inconsistency likely reflects:

• Heterogeneous fibromyalgia populations with different comorbidities (especially depression and PTSD)
• Different cortisol sampling methods (salivary, urinary, serum, hair)
• Failure to account for time-of-day, menstrual phase, medications, and BMI
• Collapsing the diurnal pattern into a single mean value

What Newer Research Suggests

Rather than asking "is cortisol high or low in fibromyalgia?", newer HPA pain research asks: "is the rhythm disrupted, and in what specific way?"

The answer that is emerging is nuanced:

• The diurnal amplitude (the difference between morning peak and evening nadir) tends to be reduced in fibromyalgia
• This can result from either a lower morning peak, a higher evening nadir, or both
• The cortisol awakening response may be blunted
• Late-day cortisol may be elevated, consistent with the 2024 MIDUS findings

This pattern — a flattened diurnal profile — is more consistently found than a simple "high" or "low" cortisol level, and it makes biological sense given what we know about how cortisol modulates neuroinflammation and central sensitization over the 24-hour cycle.

Hair Cortisol as a Novel Biomarker in Fibromyalgia

One methodological advance worth noting is the use of hair cortisol concentration (HCC) as a measure of long-term cortisol exposure — typically reflecting 1–3 months of secretion. Hair cortisol avoids the high moment-to-moment variability of saliva and serum and does not require multiple timed samples.

Some fibromyalgia studies using hair cortisol have found elevated HCC compared to controls, suggesting chronically elevated cortisol output over weeks to months, even when spot readings are unremarkable. This underscores that the timing, pattern, and cumulative burden of cortisol secretion all matter.

★★★★★ 4.8 · 1,247 reviews

The Adaptogens Your Nervous System Has Been Missing.

Ashwagandha, rhodiola, and phosphatidylserine — clinically-studied ingredients that support healthy cortisol rhythms.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Cortisol Pain Sensitivity: The Neuroscience

Cortisol pain sensitivity research examines how cortisol levels — both acutely and chronically — affect the threshold at which stimuli are perceived as painful, and the magnitude of pain responses.

Acute Cortisol: Stress-Induced Analgesia

Under acute stress, cortisol is part of a constellation of hormonal changes (including endorphin, adrenaline, and noradrenaline release) that produce stress-induced analgesia — a transient increase in pain tolerance that helps organisms cope with acute threats.

This is why soldiers sometimes report not noticing significant injuries until after combat, or why athletes can complete a race despite what later proves to be a serious injury. In these contexts, cortisol acts as a pain suppressant.

Cortisol pain threshold research has demonstrated this acute analgesic effect in laboratory settings using cold pressor tasks, ischemic pain tests, and pressure algometry. Subjects given exogenous cortisol or who mount large cortisol responses to a stressor typically show elevated pain thresholds in the short term.

Chronic Cortisol Dysregulation: Pain Amplification

The situation reverses dramatically with chronic dysregulation. Prolonged or blunted cortisol signaling is associated with:

• Reduced pain threshold (lower stimulus intensity needed to evoke pain)
• Increased temporal summation (progressive amplification of pain with repeated identical stimuli)
• Impaired conditioned pain modulation (a test of descending inhibition)
• Increased pressure pain sensitivity, particularly at sites remote from any injury

These effects reflect both central sensitization processes and peripheral sensitization through impaired anti-inflammatory control.

The cortisol pain threshold research literature therefore reveals a paradox: cortisol is acutely analgesic, but its chronic dysregulation is pronociceptive. The critical variable is not cortisol per se, but the pattern of its secretion over time.

The Role of Glucocorticoid Receptor Resistance

One mechanism linking chronic HPA dysregulation to heightened pain sensitivity is glucocorticoid receptor (GR) resistance — a state in which target cells become less responsive to cortisol signaling, even when cortisol levels are not dramatically abnormal.

GR resistance has been documented in chronic fatigue, PTSD, and inflammatory pain states. When GR signaling is impaired, cortisol loses its anti-inflammatory and pain-suppressive effects. The body produces cortisol, but the tissue cannot respond to it appropriately — leaving inflammation and sensitization unchecked.

HPA Pain Research in Specific Conditions

Low Back Pain

Chronic pain HPA research in low back pain has yielded mixed results, consistent with the heterogeneity of low back pain itself. Studies that differentiate between specific subgroups — particularly those with high levels of central sensitization features, fear-avoidance, and psychosocial distress — are more likely to find meaningful cortisol alterations.

The 2025 review on cortisol and DHEA/S (PubMed 39997049) touched on chronic musculoskeletal pain broadly, noting that the ratio of cortisol to DHEA may be as informative as cortisol alone — with an elevated cortisol-to-DHEA ratio reflecting a catabolic, pro-inflammatory state that may amplify musculoskeletal pain.

Osteoarthritis

The 2020 systematic review (PubMed 32156623) that examined cortisol in osteoarthritis and broader chronic pain populations found inconsistent evidence overall. Three studies suggested elevated cortisol in pain patients, but all were rated low quality with high risk of bias.

This honest null-to-weak finding is valuable. It tells us that in osteoarthritis — a condition with prominent peripheral structural drivers — the cortisol signal may be weaker than in conditions like fibromyalgia or widespread pain where central mechanisms dominate.

Acute Musculoskeletal Trauma

A 2024 study examined cortisol as a marker of pain and distress following acute musculoskeletal trauma (PubMed 38168023). The main-effect result was negative — no overall association between cortisol and pain or distress levels was found.

However, stratified analyses revealed important subgroup interactions:

• In younger individuals, cortisol was more strongly associated with distress prediction
• In individuals with low pretrauma stress, cortisol showed significant interactions with distress outcomes

This finding illustrates that the cortisol-pain relationship is profoundly context-dependent. Age, pre-existing stress burden, BMI, and other individual factors modulate how cortisol relates to pain outcomes — a finding that has major implications for how we design and interpret future stress pain research.

Neuropathic Pain

HPA pain research in neuropathic conditions (diabetic neuropathy, postherpetic neuralgia, complex regional pain syndrome) is less developed than in musculoskeletal pain, but early evidence suggests HPA dysregulation is present and may be particularly marked in CRPS, where the sympathetic and HPA systems are both substantially dysregulated.

Stress, Trauma, and the Cortisol-Pain Nexus

Stress pain research has consistently shown that psychological stress is one of the most powerful modulators of both cortisol secretion and pain processing — and that this relationship has profound clinical implications.

Adverse Childhood Experiences and HPA Programming

Adverse childhood experiences (ACEs) — abuse, neglect, household dysfunction — permanently alter HPA axis development. Adults with high ACE scores show altered diurnal cortisol patterns, blunted stress reactivity, and significantly elevated rates of chronic pain conditions including fibromyalgia, chronic pelvic pain, and chronic widespread pain.

The biological mechanism involves epigenetic programming of glucocorticoid receptor expression, particularly in the hippocampus, which is critical for HPA negative feedback. Early adversity can permanently reduce hippocampal GR density, impairing cortisol suppression and increasing vulnerability to later stress-induced pain.

PTSD and the Chronic Pain-PTSD Overlap

The co-occurrence of PTSD and chronic pain is striking — rates of chronic pain in PTSD populations range from 35% to 80% depending on the population and pain definition. Cortisol chronic pain mechanism research in this comorbid group reveals a particularly disrupted HPA profile, often characterized by hypocortisolism (paradoxically low cortisol despite the hyperarousal state), impaired negative feedback, and profoundly flattened diurnal rhythms.

This PTSD-pain-HPA triad creates a particularly challenging clinical picture where standard analgesic approaches are often insufficient without addressing the trauma-related HPA dysregulation.

Chronic Workplace and Psychosocial Stress

The 2025 cohort study's use of a community-dwelling (non-clinical) sample is significant because it captures the full spectrum of chronic psychological stress — not just clinical PTSD, but everyday work stress, relationship stress, financial strain, and other sustained psychosocial burdens.

That blunted cortisol rhythms in this community population predicted later chronic pain underscores that you do not need dramatic trauma to shift cortisol rhythms toward a pain-promoting profile. Chronic low-level psychosocial stress — the kind most middle-aged adults experience — is sufficient.

This is consistent with the 2024 MIDUS findings, which came from a large representative community sample of midlife Americans, not from a clinical pain population.

Is Cortisol a Useful Biomarker for Chronic Pain?

Given the evidence reviewed above, can clinicians or researchers use cortisol as a practical biomarker for chronic pain risk or severity?

The Case For

• The 2025 prospective study shows that blunted post-wake cortisol decline predicts chronic multisite pain with ORs of 1.93–2.73, which are clinically meaningful effect sizes
• Salivary cortisol is relatively non-invasive and can characterize the diurnal profile with as few as 4–6 timed samples
• Hair cortisol provides an integrated measure of long-term cortisol output without requiring timed sampling
• Cortisol rhythm measures may identify at-risk individuals before pain becomes chronic, opening a prevention window

The Case Against (or For Caution)

• Cortisol variability is enormous — it is affected by sleep quality, mood, medications, BMI, menstrual cycle, caffeine, smoking, and the time and conditions of sample collection
• No standardized, validated clinical protocol exists for using cortisol as a chronic pain biomarker
• Sensitivity and specificity for any specific cortisol measure as a pain predictor remain insufficient for individual clinical decision-making
• The 2020 systematic review found that at the group level, cortisol findings across chronic pain studies are inconsistent, particularly for localized pain conditions
• The 2024 acute trauma study found no main-effect cortisol-pain association, underscoring that cortisol is not straightforwardly predictive in all contexts

The practical conclusion is that cortisol rhythm measures — particularly measures of diurnal slope and post-wake decline — show promise as population-level risk indicators and research biomarkers, but are not yet ready for routine individual clinical use. Clinically, however, the signs of HPA dysregulation (fatigue, disrupted sleep, flat energy throughout the day, worsening pain with stress) remain meaningful clinical cues that warrant attention.

★★★★★ 4.8 · 1,247 reviews

See Why Athletes And Executives Take It Daily.

Adaptogen-based formula, third-party tested, made in the USA. Cancel subscription anytime.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Confounders: Sleep, Depression, Anxiety, and Age

No discussion of cortisol chronic pain mechanism research is complete without acknowledging the profound confounding that these studies must navigate.

Sleep

Sleep is perhaps the most powerful confounder in the cortisol-pain relationship. Poor sleep:

• Flattens the diurnal cortisol rhythm
• Increases pain sensitivity via central sensitization mechanisms
• Is highly prevalent in chronic pain populations

This creates a three-way interaction in which it is extremely difficult to determine whether cortisol dysregulation is driving the pain signal, the sleep signal, or is itself driven by sleep disruption. Studies that fail to account for sleep quality may be measuring sleep dysregulation as much as primary HPA dysfunction.

Depression and Anxiety

Depression is associated with altered cortisol profiles (hypercortisolism in melancholic depression, hypocortisolism in atypical depression), and depression is highly comorbid with chronic pain. Similarly, anxiety disorders are associated with elevated cortisol reactivity.

Studies of cortisol fibromyalgia that fail to adequately control for depression may be detecting the cortisol signature of depression rather than fibromyalgia-specific HPA changes.

Critically, the 2025 cohort study did attempt to adjust for relevant confounders — this methodological care strengthens confidence in its findings — but in the broader literature, inadequate depression control remains a common limitation.

Age and Sex

Cortisol rhythms change with age, with older adults typically showing flatter diurnal profiles. The 2024 acute trauma study found that the cortisol-distress association was modulated by age, with younger individuals showing stronger effects. Sex also matters: the HPA axis is significantly modulated by sex hormones, and women — who are disproportionately affected by fibromyalgia and chronic widespread pain — show different cortisol dynamics than men, particularly across the menstrual cycle and at menopause.

BMI

Higher BMI is associated with elevated cortisol, greater inflammation, and greater chronic pain burden. The 2024 trauma study identified BMI as a significant moderator of cortisol-pain associations. Studies that do not stratify or adjust for BMI may obscure or inflate cortisol-pain relationships.

Medications

Opioids, glucocorticoids, antidepressants, and benzodiazepines — all commonly used in chronic pain populations — significantly affect cortisol measurement. This is a critical methodological challenge for any clinical study of cortisol in pain patients.

What Treatments Can Normalize Cortisol in Chronic Pain?

Given the evidence linking HPA dysregulation to chronic pain vulnerability, an obvious clinical question follows: can normalizing cortisol rhythms reduce pain, and if so, how?

It is important to be clear upfront that no treatment has been proven through high-quality RCTs to reduce chronic pain primarily via cortisol normalization. However, several evidence-based interventions for chronic pain are known to also normalize cortisol profiles, and this shared mechanism may contribute to their effectiveness.

Sleep Optimization

Given the tight coupling between sleep and cortisol rhythm, improving sleep quality is likely the single most impactful behavioral intervention for cortisol rhythm normalization. Cognitive behavioral therapy for insomnia (CBT-I) has strong evidence for improving sleep in chronic pain and is associated with reductions in pain severity — improvements in cortisol rhythm may be a mediating mechanism.

Exercise

Regular aerobic exercise normalizes HPA axis reactivity, increases diurnal cortisol amplitude (steeper morning peak, lower evening levels), and is one of the most consistently effective non-pharmacological interventions for chronic pain. Mechanistically, exercise may partially work by restoring healthy cortisol rhythms and improving glucocorticoid receptor sensitivity.

Mindfulness-Based Stress Reduction (MBSR)

MBSR and related mindfulness interventions have been shown to reduce late-day cortisol, improve diurnal rhythm amplitude, and reduce chronic pain. The mechanism involves both HPA regulation (via prefrontal cortex modulation of the limbic-HPA system) and changes in central pain processing.

Psychological Therapies Targeting Trauma and Stress

Since trauma history and chronic psychosocial stress are major drivers of HPA dysregulation, therapies that directly address these — including EMDR, trauma-focused CBT, and acceptance and commitment therapy (ACT) — may normalize cortisol profiles alongside their psychological benefits.

Pharmacological Considerations

Low-dose naltrexone (LDN) has attracted interest in fibromyalgia and chronic widespread pain, with proposed mechanisms involving microglial modulation and HPA effects. Preliminary evidence is promising, but robust RCT data on cortisol normalization specifically are lacking.

Some researchers have explored whether targeted cortisol-modulating agents (such as glucocorticoid receptor sensitizers or CRH antagonists) might have a role in chronic pain, particularly in high-HPA-dysfunction phenotypes — but this remains firmly in the research domain.

Clinical Takeaways for Practitioners and Patients

Let's consolidate the most clinically actionable insights from this review of cortisol and chronic pain research:

For Clinicians

1. Think diurnal rhythm, not single readings A spot cortisol level will rarely tell you much about a patient's chronic pain. If you are interested in HPA assessment, diurnal salivary profiles (morning, midday, evening) or hair cortisol provide more meaningful information.

2. Screen for HPA dysregulation features clinically Fatigue that is worst on waking (not refreshed by sleep), flat energy throughout the day, worsening pain with stress and sleep disruption, and high allostatic load are all signs of HPA dysregulation worth addressing regardless of whether you measure cortisol.

3. Widespread pain as a central sensitization signal The 2025 study's selectivity for multisite chronic pain supports using the pattern of pain distribution as a clinical clue. Multisite pain with features of central sensitization (allodynia, hyperalgesia, fatigue, cognitive symptoms) may be particularly linked to HPA dysregulation.

4. Address comorbid sleep disturbance and stress actively These are not just quality-of-life issues — they are likely mechanistically central to HPA-driven pain amplification.

5. Trauma history matters A thorough ACE and trauma history is relevant to understanding HPA dysfunction in complex chronic pain patients.

For Patients

1. Your body's stress system affects your pain Research increasingly shows that how your cortisol rhythm is organized across the day can influence whether pain becomes chronic and widespread. This is not about "pain being in your head" — it is about real neuroendocrine biology.

2. Sleep is medicine for pain Improving sleep quality is one of the most evidence-supported things you can do to support both cortisol rhythm normalization and pain reduction.

3. Chronic stress has biological consequences for pain Sustained psychological stress — whether from work, relationships, finances, or unprocessed trauma — can alter your cortisol rhythm in ways that lower your pain threshold.

4. Exercise genuinely helps Even moderate regular movement helps normalize cortisol patterns and reduces pain sensitivity. The benefits are real and partly mediated through these neuroendocrine pathways.

★★★★★ 4.8 · 1,247 reviews

Ready To Try Adaptogen-Based Cortisol Support?

Third-party tested. 60-day guarantee. Free shipping over $40. Ships in 24 hours.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Frequently Asked Questions

Does chronic pain raise cortisol, or does abnormal cortisol contribute to chronic pain?

Based on current evidence, the relationship is bidirectional. Chronic pain is a stressor that can dysregulate cortisol, but the 2025 prospective cohort study demonstrates that blunted diurnal cortisol decline can precede the development of chronic pain, suggesting HPA dysregulation also acts as a risk factor. The two processes likely reinforce each other over time.

Is cortisol higher or lower in people with chronic pain?

The answer is genuinely "it depends." The 2020 systematic review found inconsistent results across studies. More important than the absolute level is the shape of the diurnal curve. Both low morning cortisol (blunted CAR) and high late-day cortisol (impaired suppression) have been found in chronic pain populations, pointing to a flattened diurnal amplitude as the most consistent finding.

Can salivary cortisol or hair cortisol predict chronic pain?

Salivary cortisol diurnal profiles show promise as a predictor of future chronic multisite pain in prospective research. Hair cortisol provides a useful integrated measure. However, neither is validated for individual clinical prediction. They are better suited to research contexts at present, though their clinical utility may grow as protocols are standardized.

What does a flattened or blunted diurnal cortisol rhythm mean?

A flattened or blunted diurnal rhythm means the normal steep morning-to-evening decline in cortisol is attenuated — cortisol levels are more similar across the day than healthy. This pattern is associated with chronic stress, burnout, poor sleep, PTSD, and — based on new cortisol chronic pain research — increased risk of developing widespread chronic pain.

Are cortisol levels useful as a biomarker for fibromyalgia, low back pain, or multisite pain?

For fibromyalgia and multisite pain, there is moderate research support for using diurnal cortisol measures as biomarkers, but they are not yet clinically ready for individual diagnosis or treatment selection. For localized low back pain, the evidence is weaker and less consistent.

How do stress, PTSD, or trauma affect cortisol and pain outcomes?

Trauma history — including adverse childhood experiences and PTSD — significantly alters HPA axis programming, typically producing blunted diurnal cortisol rhythms and impaired stress reactivity. These changes lower pain thresholds and increase vulnerability to chronic widespread pain. Addressing trauma history is therefore clinically relevant in complex chronic pain cases.

Can sleep, anxiety, or depression change the cortisol-pain relationship?

Yes, substantially. Sleep disruption flattens cortisol rhythms and amplifies pain. Depression and anxiety independently alter cortisol profiles. These are not merely confounders — they are part of the biopsychosocial web in which the chronic pain HPA relationship is embedded. Treating these conditions can normalize both cortisol and pain outcomes.

What treatments can normalize cortisol in chronic pain?

Aerobic exercise, CBT-I (cognitive behavioral therapy for insomnia), mindfulness-based stress reduction, and trauma-focused psychological therapies all have evidence for normalizing cortisol diurnal profiles alongside their other pain benefits. No drug has yet been approved specifically to treat chronic pain via cortisol normalization, but this remains an active research area.

Conclusion

The science of cortisol and chronic pain has come a long way from the simple question of whether cortisol is "high" or "low." The most important conceptual shift in recent years — crystallized by the 2025 prospective cohort study and supported by the 2024 MIDUS findings — is that the rhythm of cortisol secretion matters more than any single value.

A blunted post-waking decline in cortisol, reflecting impaired diurnal amplitude, is associated with approximately double the odds of developing chronic multisite pain over a 7.6-year follow-up. This is not a trivial effect size. It positions HPA rhythm disruption as a genuine modifiable risk factor — not merely a downstream consequence — of chronic widespread pain.

The mechanisms are increasingly clear: disrupted cortisol central sensitization pathways, impaired glucocorticoid receptor sensitivity, loss of anti-inflammatory cortisol pulsatility, neuroinflammation, and sleep disruption all form a reinforcing web that the chronic pain HPA literature is beginning to map in detail.

For cortisol fibromyalgia specifically, and for chronic multisite pain more broadly, the future of research and clinical care likely lies in characterizing individual HPA rhythm phenotypes and matching them to targeted behavioral and potentially pharmacological interventions.

The integration of HPA pain research into mainstream pain neuroscience education is overdue. Cortisol is not just a stress hormone — it is a pain biology hormone, and understanding its rhythmic behavior may be essential to preventing and treating some of our most challenging chronic pain conditions.

This post is intended for educational purposes and should not replace individualized medical advice. If you are experiencing chronic pain, please consult a qualified healthcare professional.

References

1. Association of diurnal cortisol rhythm with chronic pain: evidence from a prospective cohort study in community-dwelling adults. PubMed 40484158 (2025).
2. Diurnal cortisol patterns in chronic pain. Stress 27:1, article 2402954 (2024). MIDUS findings PDF, midus.wisc.edu.
3. Cortisol as a marker of pain and distress after acute musculoskeletal trauma. PubMed 38168023 (2024).
4. Systematic review: cortisol in osteoarthritis and chronic pain. PubMed 32156623 (2020).
5. Cortisol and DHEA/S in acute and chronic pain, aging, and related disease states. PubMed 39997049 (2025).
6. Diurnal cortisol profiles and pain sensitivity — PMC review. PMC4263906.